# BCG With or Without Gefitinib in Treating Patients With High-Risk Bladder Cancer

> **NCT00352079** · PHASE3 · TERMINATED · sponsor: **NCIC Clinical Trials Group** · enrollment: 41 (actual)

## Conditions studied

- Bladder Cancer

## Interventions

- **BIOLOGICAL:** BCG vaccine
- **DRUG:** gefitinib
- **PROCEDURE:** quality-of-life assessment

## Key facts

- **NCT ID:** NCT00352079
- **Lead sponsor:** NCIC Clinical Trials Group
- **Sponsor class:** NETWORK
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-01-04
- **Primary completion:** 2012-01-06
- **Final completion:** 2012-01-06
- **Target enrollment:** 41 (ACTUAL)
- **Why stopped:** terminated due to poor accrual
- **Last updated:** 2023-08-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00352079

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00352079, "BCG With or Without Gefitinib in Treating Patients With High-Risk Bladder Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00352079. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*